The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
S | Sensory organs | |
2
|
S01 | Ophthalmologicals | |
3
|
S01L | Ocular vascular disorder agents | |
4
|
S01LA | Antineovascularisation agents | |
5
|
S01LA04 | Ranibizumab |
| Active Ingredient |
|---|
|
Ranibizumab is a humanised recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A (VEGF-A). It binds with high affinity to the VEGF-A isoforms, thereby preventing binding of VEGF-A to its receptors VEGFR-1 and VEGFR-2. Binding of VEGF-A to its receptors leads to endothelial cell proliferation and neovascularisation, as well as vascular leakage, all of which are thought to contribute to the progression of the neovascular form of age-related macular degeneration, pathologic myopia and CNV or to visual impairment caused by either diabetic macular oedema or macular oedema secondary to RVO in adults and retinopathy of prematurity in preterm infants. |
| Document | Type | Information Source | |
|---|---|---|---|
| BYOOVIZ Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) | |
| LUCENTIS Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) | |
| RANIVISIO Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) | |
| RIMMYRAH Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) | |
| XIMLUCI Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.